Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RFA for small renal tumors holds up over long term

Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045

Publish date:: October 4, 2018

Key clinical point: Radiofrequency ablation of small renal tumors is safe and effective.

Major finding: In 106 patients with small renal masses, disease-free survival was 89% at 6 years post procedure.

Study details: Retrospective cohort study of 106 patients with 112 tumors, followed up to 10 years.

Disclosures: The authors reported no conflicts of interest and no outside sources of funding.

Source: Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045.

Read the article.

Citation:

Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Renal Cell Carcinoma

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Fear of recurrence highly prevalent in RCC survivors,

Risk factors for severe immune-related AEs identified,

Pembrolizumab plus axitinib continues to outshine sunitinib for advanced RCC,

All Specialties